Home Blog Page 2303

ANTHONY, LINDER & CACOMANOLIS, PLLC EXPANDS REACH WITH BILINGUAL BLOG LAUNCH

WEST PALM BEACH, Fla., Oct. 10, 2025 /PRNewswire/ — Anthony, Linder & Cacomanolis, PLLC (“ALC”) a premier international corporate and securities law firm, is excited to announce that its renowned securities law and capital markets blog will now be published in both English and Japanese. This strategic expansion aims to better serve its diverse audience and enhance accessibility to crucial legal insights in the global market.

Key Highlights:

  • Bilingual Publication: The blog will feature articles and insights in both English and Japanese, catering to a broader audience.
  • Established Resource: Launched in 2010, the blog has been published weekly since its inception and is available at www.securitieslawblog.com.
  • Expert Contributions: Laura Anthony, founding partner at ALC, personally researches and writes the blog, earning her the respect of market participants at all levels.
  • Industry Recognition: Securitieslawblog is well-known for providing comprehensive information on capital markets and securities laws, including up-to-date information on regulations, regulatory changes, and market trends.

ALC’s Role in Japanese U.S. Listings:

ALC has become a go-to legal advisor for Japanese companies pursuing U.S. listings on the Nasdaq and NYSE via initial public offerings (IPOs), direct listings, and de-SPAC transactions. The firm has advised on some of the most innovative cross-border offerings to date, including:

  • The first-ever U.S. IPOs on each of the Nasdaq and NYSE involving Japanese common shares, rather than American Depository Receipts (ADRs)—a concept initially championed by ALC several years ago.
  • A strong track record with over a dozen Japanese clients seeking U.S. IPOs on the Nasdaq and NYSE, recognizing Japan as the next U.S. IPO epicenter, surpassing China in favorability in U.S. markets.

Commitment to Client Success:

“We’re honored to serve as counsel to some of the most dynamic companies coming out of Japan,” said Laura Anthony, ALC Founding Partner. “Our work goes beyond legal guidance—we help global businesses realize their growth ambitions through strategic, innovative, and compliant U.S. market access.”

Contact:

Laura Anthony, Founding Partner
Anthony, Linder & Cacomanolis, PLLC
lanthony@alclaw.com

About Anthony, Linder & Cacomanolis

Anthony, Linder & Cacomanolis, PLLC is a leading law firm specializing in securities law and capital markets. With a strong international presence and an unwavering commitment to excellence, ALC continues to lead the way in advising companies navigating the complex intersection of global law and capital markets.  The Anthony, Linder & Cacomanolis team represents issuers and underwriters and has completed transactions valued in excess of $25 billion.  For more information please visit www.alclaw.com or contact us at 844-281-2863.

Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)

  • EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR)
  • Celltrion plans to enter the U.S. ophthalmology market to meet diverse needs of patients suffering from various eye conditions

INCHEON, South Korea, Oct. 10, 2025 /PRNewswire/ — Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept), for the treatment of neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR).[1]

Aflibercept is a VEGF inhibitor formulated as an injection for the eye that blocks the growth of new blood vessels and decreases the ability of fluid to pass through blood vessels (vascular permeability) in the eye by blocking VEGF-A and placental growth factor (PlGF), two growth factors involved in ocular angiogenesis.

“Timely access to effective therapies is essential for individuals affected by retinal diseases. We are proud to have EYDENZELT approved by the FDA, and we look forward to expanding the availability and access of biological treatments across the U.S.,” said Dr. Juby Jacob-Nara, Senior Vice President and Chief Medical Officer at Celltrion USA. “With EYDENZELT demonstrating biosimilarity to its reference product, we believe this approval will mark a significant milestone in the treatment landscape of retinal diseases—helping physicians broaden their options and improving patient outcomes.”

The FDA approval was based on a totality of evidence including analytical, nonclinical, and clinical data. In a randomized, double-masked, parallel-group, multicenter phase III study of EYDENZELT, the efficacy, safety, pharmacokinetics, and immunogenicity of EYDENZELT was compared to EYLEA in patients with diabetic macular edema (DME). The 52-week trial included 348 patients with DME. The primary endpoint was the change in best corrected visual acuity measured at week 8 from baseline, comparing EYDENZELT and EYLEA. Results of the study showed that EYDENZELT met the predefined equivalence criteria, and secondary endpoints of efficacy, safety, and immunogenicity also showed trends similar to EYLEA.

“Advanced age-related macular degeneration (AMD) is a leading cause of irreversible blindness and visual impairment in the world and nearly 20 million people in the U.S. are living with some form of age-related macular degeneration,” said Dr. David M. Brown, Director, Retina Consultants of Texas Research Centers, Co-chair, Medical Leadership Board Retina Consultants of America. “EYDENZELT will be an important new addition to our options for the treatment of our patients with serious retinal diseases.”

EYDENZELT is Celltrion’s first FDA-approved biologic product in ophthalmology. EYDENZELT was also approved by the European Commission (EC) in February 2025.   

###

About EYDENZELT® (aflibercept-boav) 

EYDENZELT® (aflibercept-boav) is a vascular endothelial growth factor (VEGF) inhibitor referencing EYLEA® (aflibercept). EYDENZELT is approved based on a comprehensive data confirming the therapeutic equivalence EYLEA. In the U.S., EYDENZELT is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (AMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME) and diabetic retinopathy (DR).

INDICATIONS

EYDENZELT® (aflibercept-boav) is indicated for the treatment of patients with:

  • Neovascular (Wet) Age-Related Macular Degeneration (AMD)
  • Macular Edema Following Retinal Vein Occlusion (RVO)
  • Diabetic Macular Edema (DME)
  • Diabetic Retinopathy (DR)

IMPORTANT SAFETY INFORMATION

  • EYDENZELT is contraindicated in patients with ocular or periocular infections, active intraocular inflammation, and hypersensitivity to aflibercept or any of the excipients in EYDENZELT.
  • Instruct patients and/or caregivers to report any signs and/or symptoms suggestive of endophthalmitis, retinal detachment, or retinal vasculitis without delay and should be managed appropriately.
  • Increases in intraocular pressure have been seen within 60 minutes of an intravitreal injection. Intraocular pressure and the perfusion of the optic nerve head should be monitored and managed appropriately.
  • There is a potential risk of arterial thromboembolic events (ATEs) following intravitreal use of VEGF inhibitors, including aflibercept products. ATEs are defined as nonfatal stroke, nonfatal myocardial infarction, or vascular death (including deaths of unknown cause).
  • The most common adverse reactions (≥5%) reported in patients receiving aflibercept were conjunctival hemorrhage, eye pain, cataract, vitreous detachment, vitreous floaters, and intraocular pressure increased.

For more information, see Full Prescribing Information.

About Celltrion, Inc.

Celltrion, Inc. is a leading biopharmaceutical company that specializes in researching, developing, manufacturing, marketing and sales of innovative therapeutics that improve people’s lives worldwide. Celltrion is a pioneer in the biosimilar space, having launched the world’s first monoclonal antibody biosimilar. Our global pharmaceutical portfolio addresses a range of therapeutic areas including immunology, oncology, hematology, ophthalmology and endocrinology. Beyond biosimilar products, we are committed to advancing our pipeline with novel drugs to push the boundaries of scientific innovation and deliver quality medicines. For more information, please visit our website www.celltrion.com/en-us and stay updated with our latest news and events on our social media: LinkedIn, Instagram, X, and Facebook.

About Celltrion USA

Celltrion USA is Celltrion’s U.S. subsidiary established in 2018. Headquartered in New Jersey, Celltrion USA is committed to expanding access to innovative biologics to improve care for U.S. patients. Celltrion currently has ten biosimilar products approved by the U.S. FDA: INFLECTRA® (infliximab-dyyb), TRUXIMA® (rituximab-abbs), HERZUMA® (trastuzumab-pkrb), VEGZELMA® (bevacizumab-adcd), YUFLYMA®(adalimumab-aaty), AVTOZMA® (tocilizumab-anho), STEQEYMA® (Ustekinumab-stba) STOBOCLO® (denosumab-bmwo), OSENVELT® (denosumab-bmwo), and OMLYCLO® (omalizumab-igec) as well as a novel biologic ZYMFENTRA® (infliximab-dyyb). Celltrion USA will continue to leverage Celltrion’s unique heritage in biotechnology, supply chain excellence and best-in-class sales capabilities to improve access to high-quality biopharmaceuticals for U.S. patients. For more information, please visit www.celltrionusa.com, and stay updated with our latest news and events on our social media: LinkedIn.

FORWARD-LOOKING STATEMENT

Certain information set forth in this press release contains statements related to our future business and financial performance and future events or developments involving Celltrion, Inc. and its subsidiaries that may constitute forward-looking statements, under pertinent securities laws.

These statements may be also identified by words such as “prepares”, “hopes to”, “upcoming”, “plans to”, “aims to”, “to be launched”, “is preparing”, “once gained”, “could”, “with the aim of”, “may”, “once identified”, “will”, “working towards”, “is due”, “become available”, “has potential to”, the negative of these words or such other variations thereon or comparable terminology.

In addition, our representatives may make oral forward-looking statements. Such statements are based on the current expectations and certain assumptions of Celltrion, Inc. and its subsidiaries’ management, of which many are beyond its control.

Forward-looking statements are provided to allow potential investors the opportunity to understand management’s beliefs and opinions in respect to the future so that they may use such beliefs and opinions as one factor in evaluating an investment. These statements are not guarantees of future performance and undue reliance should not be placed on them.

Such forward-looking statements necessarily involve known and unknown risks and uncertainties associated with the company’s business, including the risk factors disclosed in its Annual Report and/or Quarterly Reports, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied by such statements.

Celltrion, Inc. and its subsidiaries undertake no obligation to update forward-looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws.

Trademarks

EYDENZELT® is a registered trademark of Celltrion, Inc.
EYLEA® is a registered trademark of Regeneron Pharmaceuticals Inc.

References

[1] EYDENZELT U.S. prescribing information (2025)

US–24-00028

For further information please contact:
Katie Gallagher
kgallagher@jpa.com
+1 617-657-1324

Alamar Biosciences Launches NULISAqpcr™ BD-pTau217 Assay: A Breakthrough in Non-Invasive, Brain-Specific Biomarker Detection for Alzheimer’s Disease Research

New Blood-Based Assay Delivers Unparalleled Sensitivity and Specificity to enable the next generation of assay development. 

FREMONT, Calif., Oct. 10, 2025 /PRNewswire/ — Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, today announced the launch of the NULISAqpcr™ BD-pTau217 Assay— a transformative leap in blood-based quantification of brain-derived phosphorylated tau 217 (pTau217)—a pivotal biomarker in Alzheimer’s disease research and other tauopathies. This first-of-its-kind assay is the only brain-derived single-plex solution available, setting a new benchmark for precision and CNS specificity in neurodegenerative disease research.

NULISA BD-pTau217 Assays
NULISA BD-pTau217 Assays

Built on Alamar’s proprietary NULISA™ platform, the NULISAqpcr BD-pTau217 Assay delivers unprecedented sensitivity and specificity from non-invasive sample types such as plasma, serum and dried blood spots. The research assay’s direct measurement of CNS-derived pTau217 without the need for cerebrospinal fluid (CSF) collection or PET imaging removes existing barriers to widespread adoption in population-based studies or longitudinal clinical trials.

“The NULISAqpcr BD-pTau217 Assay redefines what’s possible in CNS biomarker quantitation,” stated Dr. Yuling Luo, Founder, Chairman and CEO of Alamar Biosciences. “By removing the noise from the peripheral sources of tau, researchers can now detect meaningful changes in the brain earlier and with higher precision.”

“The performance of Alamar’s brain-specific plasma pTau217 assays is excellent,” said Jonathan Schott, MD, PhD, Professor of Neurology, University College London. “For the detection of Alzheimer’s pathology with cognitive symptoms, our early results suggest that the single-plex format performs at least as well as established plasma ptau217 tests, but has a higher fold-change, and results in fewer samples being classified in the indeterminate range. In a research setting, brain-specific pTaus measured using the multiplex assay show great promise in detecting asymptomatic individuals with high levels of Alzheimer’s pathology who may be candidates for clinical trials of disease modifying therapies.”

Available as a single-plex NULISAqpcr assay or within the multiplex NULISAseq™ CNS Disease Panel 120, the BD-pTau217 assay will support both discovery and translational research. The assay’s automated workflow enables processing of over 220 samples per day with the ARGO™ HT System, making it ideal for high-throughput analysis in disease cohorts or population-based studies. 

Alamar Biosciences continues to collaborate with the neuroscience community to unlock biomarker insights that accelerate progress in Alzheimer’s and beyond. Visit alamarbio.com to learn more.

The NULISA BD-pTau217 Assays are for research use only and not for use in diagnostic procedures.

About Alamar Biosciences, Inc.
Alamar Biosciences is a privately held life sciences company with a mission to power precision proteomics to enable the earliest detection of disease. The company’s proprietary NULISA™ Platform along with the ARGO™ HT System work seamlessly with the latest advances in genomics to achieve single digit attomolar detection sensitivity, greatly surpassing the most sensitive protein detection technology on the market today. For more information, please visit alamarbio.com.


 

Amcor Appoints Stephen R. Scherger as Executive Vice President and Chief Financial Officer

Michael Casamento to return home to Australia to be closer to his family on a full-time basis; Will leave the Company as a result, remaining in an advisory role until June 30, 2026 to support transition

Company reaffirms Fiscal 2026 and first quarter Fiscal 2026 outlook

ZURICH, Oct. 10, 2025 /PRNewswire/ — Amcor (NYSE: AMCR, ASX: AMC), a global leader in consumer packaging and dispensing solutions for Nutrition, Health, Beauty and Wellness, announced the appointment of Stephen R. Scherger as Executive Vice President and Chief Financial Officer, effective Nov. 10, 2025. Mr. Scherger succeeds Michael Casamento, who after ten years as Amcor’s Chief Financial Officer has decided to return home to Australia to be closer to his family on a full-time basis and will leave the Company as a result. Mr. Casamento will remain as an advisor to the Company until June 30, 2026, to help support a smooth transition.

Stephen R. Scherger
Stephen R. Scherger

Michael Casamento
Michael Casamento

Mr. Scherger brings more than 30 years of finance, operations and strategy experience in the packaging industry. Most recently, he served as Executive Vice President and Chief Financial Officer of Graphic Packaging since 2015, where he played a leading role in transforming Graphic Packaging into the world’s largest producer of fiber-based packaging, including supporting the integration and synergy realization for a number of large-scale acquisitions. During his tenure, Graphic Packaging’s net sales more than doubled to nearly $9 billion and net income nearly tripled.

Amcor CEO Peter Konieczny commented, “On behalf of the Board, I’m pleased to welcome Steve to the Amcor team. His deep industry experience, unique understanding of the U.S. and global packaging markets and team-oriented leadership style make him a natural fit for Amcor. His proven track record of enhancing growth and profitability at lean, global businesses will further enhance Amcor’s ability to deliver near- and long-term value for customers and shareholders.”

“It is a privilege to join Amcor as CFO,” commented Scherger. “Amcor has established itself as a global leader and innovator in the packaging industry, especially after the Berry Global acquisition. I am honored and excited to join the team at this time and contribute to delivering the ongoing integration commitments, the identified portfolio optimization and driving long-term organic growth.”

Konieczny continued, “On behalf of the Amcor team, I’d like to thank Michael for more than a decade of service, which concludes with Amcor being better positioned than ever following our successful combination with Berry Global. His contributions and leadership have been outstanding and he has played a significant role in laying the foundation for years of success. We wish him all the best as he returns to Australia.”

Reaffirms Fiscal 2026 and First Quarter Fiscal 2026 outlook 

Amcor reaffirmed its first quarter and fiscal year 2026 outlook, as provided in connection with fourth quarter and fiscal year 2025 financial results on Aug. 14, 2025. The Company continues to expect Adjusted EPS of 80-83 cps, representing 12-17% constant currency growth, and Free Cash Flow of $1.8-1.9 billion for fiscal year 2026.  For the first quarter, Amcor also expects Adjusted EPS to be within the previously announced 18-20 cps range.

About Stephen Scherger

From 2015 to 2025, Mr. Scherger served as Chief Financial Officer of Graphic Packaging (NYSE: GPK), a publicly traded provider of fiber-based packaging solutions to food, beverage, foodservice, and other consumer products companies. From 2014 to 2015 he served as Senior Vice President, Finance of Graphic Packaging and from 2012 to 2014, he served as Senior Vice President, Consumer Packaging of Graphic Packaging, where he had direct responsibility for a $2.1 billion business comprising approximately 6,000 employees and 28 manufacturing facilities. He spent the first 25 years of his career at MeadWestvaco, where he served in finance, operations and strategy roles of increasing responsibility, ultimately assuming the role of President of the company’s $1.3 billion Beverage and Consumer Electronics business. Mr. Scherger is a member of the Board of Directors of Middleby Corporation (NASDAQ: MIDD), serving as a member of the Audit Committee and Chair of the Compensation Committee.

About Amcor

Amcor is the global leader in developing and producing responsible consumer packaging and dispensing solutions across a variety of materials for nutrition, health, beauty and wellness categories. Our global product innovation and sustainability expertise enables us to solve packaging challenges around the world every day, producing a range of flexible packaging, rigid packaging, cartons and closures that are more sustainable, functional and appealing for our customers and their consumers. We are guided by our purpose of elevating customers, shaping lives and protecting the future. Supported by a commitment to safety, over 75,000 people generate $23 billion in annualized sales from operations that span over 400 locations in more than 40 countries. NYSE: AMCR; ASX: AMC

www.amcor.com | LinkedIn | YouTube 

Cautionary Statement Regarding Forward-Looking Statements

Unless otherwise indicated, references to “Amcor,” the “Company,” “we,” “our,” and “us” in this document refer to Amcor plc and its consolidated subsidiaries. This document contains certain statements that are “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements are generally identified with words like “believe,” “expect,” “target,” “project,” “may,” “could,” “would,” “approximately,” “possible,” “will,” “should,” “intend,” “plan,” “anticipate,” “commit,” “estimate,” “potential,” “ambitions,” “outlook,” or “continue,” the negative of these words, other terms of similar meaning, or the use of future dates. Such statements are based on the current expectations of the management of Amcor and are qualified by the inherent risks and uncertainties surrounding future expectations generally. Actual results could differ materially from those currently anticipated due to a number of risks and uncertainties. Neither Amcor nor any of its respective directors, executive officers, or advisors, provide any representation, assurance, or guarantee that the occurrence of the events expressed or implied in any forward-looking statements will actually occur or if any of them do occur, what impact they will have on the business, results of operations or financial condition of Amcor. Should any risks and uncertainties develop into actual events, these developments could have a material adverse effect on Amcor’s business, including the ability to successfully realize the expected benefits of the merger of Amcor and Berry Global Group, Inc. Risks and uncertainties that could cause actual results to differ from expectations include, but are not limited to: risks arising from the integration of the Amcor and Berry Global Group, Inc., (“Berry Global”) businesses as a result of the Merger completed on April 30, 2025 (the “Transaction”); risk of continued substantial and unexpected costs or expenses resulting from the Transaction; risk that the anticipated benefits of the Transaction may not be realized when expected or at all; risk that the Company’s significant indebtedness may limit its flexibility and increase its borrowing costs; risk that the Merger related tax liabilities could have a material impact on the Company’s financial results; changes in consumer demand patterns and customer requirements in numerous industries; risk of loss of key customers, a reduction in their production requirements, or consolidation among key customers; significant competition in the industries and regions in which we operate; an inability to expand our current business effectively through either organic growth, including product innovation, investments, or acquisitions; challenging global economic conditions; impacts of operating internationally; price fluctuations or shortages in the availability of raw materials, energy and other inputs, which could adversely affect our business; production, supply, and other commercial risks, including counterparty credit risks, which may be exacerbated in times of economic volatility; pandemics, epidemics, or other disease outbreaks; an inability to attract, develop, and retain our skilled workforce and manage key officer and employee transitions; labor disputes and an inability to renew collective bargaining agreements at acceptable terms; physical impacts of climate change; significant disruption at key manufacturing facilities; cybersecurity risks, which could disrupt our operations or risk of loss of our sensitive business information; failures or disruptions in our information technology systems which could disrupt our operations, compromise customer, employee, supplier, and other data; rising interest rates that increase our borrowing costs on our variable rate indebtedness and could have other negative impacts; foreign exchange rate risk; a significant write-down of goodwill and/or other intangible assets; a failure to maintain an effective system of internal control over financial reporting; an inability of our insurance policies, including our use of a captive insurance company, to provide adequate protection against all of the key operational risks we face; an inability to defend our intellectual property rights or intellectual property infringement claims against us; litigation, including product liability claims or litigation related to Environmental, Social, and Governance (“ESG”) matters, or regulatory developments; increasing scrutiny and changing expectations from investors, customers, suppliers, and governments with respect to our ESG practices and commitments resulting in additional costs or exposure to additional risks; changing ESG government regulations including climate-related rules; changing environmental, health, and safety laws; changes in tax laws or changes in our geographic mix of earnings; and changes in trade policy, including tariff and custom regulations or failing to comply with such regulations. These risks and uncertainties are supplemented by those identified from time to time in our filings with the Securities and Exchange Commission (the “SEC”), including without limitation, those described under Part I, “Item 1A – Risk Factors” in our Annual Report on Form 10-K for the fiscal year ended June 30, 2025, and as updated by our quarterly reports on Form 10-Q. You can obtain copies of Amcor’s filings with the SEC for free at the SEC’s website (www.sec.gov). Forward-looking statements included herein are made only as of the date hereof and Amcor does not undertake any obligation to update any forward-looking statements, or any other information in this communication, as a result of new information, future developments or otherwise, or to correct any inaccuracies or omissions in them which become apparent, except as expressly required by law. All forward-looking statements in this communication are qualified in their entirety by this cautionary statement.

Presentation of non-GAAP information

Included in this release are measures of financial performance that are not calculated in accordance with U.S. GAAP, including adjusted earnings per share and adjusted free cash flow. In arriving at these non-GAAP measures, we exclude items that either have a non-recurring impact on the income statement or which, in the judgment of our management, are items that, either as a result of their nature or size, could, were they not singled out, potentially cause investors to extrapolate future performance from an improper base. Management has used and uses these measures internally for planning, forecasting and evaluating the performance of the Company’s reporting segments and certain of the measures are used as a component of Amcor’s Board of Directors’ measurement of Amcor’s performance for incentive compensation purposes. Amcor believes that these non-GAAP measures are useful to enable investors to perform comparisons of current and historical performance of the Company. These non-GAAP financial measures should not be construed as an alternative to results determined in accordance with U.S. GAAP. The Company provides guidance on a non-GAAP basis as we are unable to predict with reasonable certainty the ultimate outcome and timing of certain significant forward-looking items without unreasonable effort.  These items include but are not limited to the impact of foreign exchange translation, restructuring program costs, asset impairments, possible gains and losses on the sale of assets, certain tax related events, and difficulty in making accurate forecasts and projections in connection with the legacy Berry Global business given recency of access to all relevant information. These items are uncertain, depend on various factors, and could have a material impact on U.S. GAAP earnings and cash flow measures for the guidance period.

POMDOCTOR LIMITED Announces Closing of Initial Public Offering

GUANGZHOU, China, Oct. 10, 2025 /PRNewswire/ — POMDOCTOR LIMITED (Nasdaq: POM) (the “Company” or “POMDOCTOR”), a leading online medical services platform for chronic diseases in China, today announced the closing of its initial public offering (the “Offering”) of 5,000,004 American Depositary Shares (“ADSs”) at a public offering price of US$4.00 per ADS. Six ADSs represent one Class A ordinary share, par value US$0.0001 per share, of the Company. The ADSs began trading on Nasdaq Global Market on October 8, 2025 under the ticker symbol “POM.”

The Company received aggregate gross proceeds of approximately US$20.0 million from the Offering, before deducting underwriting discounts and other related expenses. In addition, the Company has granted the underwriters an option to purchase up to an additional 750,000 ADSs, exercisable within 45 days from the date of the final prospectus at the public offering price, less underwriting discounts.

The Offering was conducted on a firm commitment basis. Joseph Stone Capital, LLC acted as the underwriter for the Offering (the “Underwriter”).

A registration statement on Form F-1 relating to the Offering has been filed with the U.S. Securities and Exchange Commission (the “SEC”) (File Number: 333-285771), as amended, and was declared effective by the SEC on September 30, 2025. The Offering was made only by means of a prospectus, forming a part of the effective registration statement. Copies of the final prospectus relating to the Offering, when available, may be obtained from Joseph Stone Capital, LLC by email at corporatefinance@josephstonecapital.com, by standard mail at 585 Stewart Avenue, Unit L60-C, Garden City, NY 11530, or by telephone at +1 888-302-5548. In addition, copies of the final prospectus relating to the Offering, when available, may be obtained via the SEC’s website at www.sec.gov.

This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company’s securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company’s securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.

About POMDOCTOR LIMITED

POMDOCTOR LIMITED is a leading online medical services platform for chronic diseases in China, ranking sixth on China’s Internet hospital market based on the number of contracted doctors in 2022, according to Frost & Sullivan. Focusing on chronic disease management and pharmaceutical services, the Company offers a one-stop platform for medical services, organically connecting patients with doctors and pharmaceutical products. The Company’s operations primarily include internet hospital and pharmaceutical supply chain, connecting users, pharmacies, suppliers, medical professionals, and other healthcare participants. Through this model, POMDOCTOR aims to enhance the efficiency and transparency of the healthcare value chain. The Company’s mission is to provide effective prevention and treatment solutions to alleviate patients’ sufferings from illnesses. Its vision is to become the most trustworthy medical and healthcare services platform. For more information, please visit the Company’s website: http://ir.7shiliu.com.

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can find many (but not all) of these statements by the use of words such as “approximates,” “believes,” “hopes,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” “plans,” “will,” “would,” “should,” “could,” “may” or other similar expressions in this prospectus. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s registration statement and other filings with the SEC.

For more information, please contact:

POMDOCTOR LIMITED
Investor Relations Department
Email: ir@7lk.com

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

Over 30,000 Eggs Donated to Help Women in Crisis This World Egg Day

  • Australian Eggs is donating 31,200 eggs to social enterprise Two Good Co to help nourish women in crisis
  • TV personalities Khanh Ong and Alice Zaslavsky will lead a cook-up alongside the Two Good team
  • Donation will contribute to Two Good Co’s yearly delivery of 30,000 nutritious meals for vulnerable women

SYDNEY, Oct. 10, 2025 /PRNewswire/ — Australian Eggs are marking World Egg Day by donating a year’s worth of eggs (31,200) to social enterprise Two Good Co, helping deliver 30,000 nutritious meals to women in crisis. With eggs back in strong supply, the initiative ensures this everyday staple is reaching those who need it most.

L-R: Khanh Ong, Rowan McMonnies, Alice Zaslavsky
L-R: Khanh Ong, Rowan McMonnies, Alice Zaslavsky

To mark the day, TV personalities Khanh Ong and Alice Zaslavsky will roll up their sleeves in the Two Good kitchen for a cook-up, preparing two delicious dishes – an Asian-Inspired Smoked Salmon Frittata and a Melt & Mix Chocolate Slab Cake – and packaging these meals to be distributed to women with lived experience of homelessness and domestic violence.

The partnership comes at a time when food insecurity is a pressing issue across Australia. At the same time, egg supply is strong and growing, with a record 7 billion eggs consumed nationwide in 2025, as of September and egg consumption growing to a new high of 267 eggs per year for each Australian.

This growth comes on the back of new community research from Australian Eggs that shows 89% of Australians agree eggs provide important nutrition, 86% see them as a vital staple food, and 68% now view them as a better source of nutrition than they did in the past.

Rowan McMonnies, Managing Director at Australian Eggs, commented: “Egg consumption is growing and World Egg Day is all about celebrating the positive impact eggs have in our lives – from their role as a nutrient-rich staple, to the way they can bring people together over a meal. This partnership with Two Good reflects that spirit, showing that something as simple as an egg can create real community impact.“

Rob Caslick, Founder of Two Good, added: “We are so grateful to Australian Eggs for this donation, which will allow us to create thousands of meals for women living in crisis. Cooking with purpose is at the heart of what we do and partnerships like this make a huge difference, helping us not only to provide nutritious meals but also to create moments of comfort and connection.”

Celebrity chef and TV personality Khanh Ong said: “Sharing food is such a simple but powerful way to show care. It’s been great to be a part of it!”

Cook, author and TV presenter Alice Zaslavsky added: “Cooking together creates connection, and it’s a privilege to be involved in a meaningful initiative like this.”

Australians can get involved and give back this World Egg Day with Two Good’s Gifts for Good, including their new cookbook collection ‘Sweet Memories’, a journey through a different sort of nourishment (the kind that nourishes the spirit). Proceeds directly support meals for women living in crisis, making it easier than ever for the public to play their part.

For recipe inspiration and ideas to celebrate World Egg Day at home, visit Australian Eggs.

Australian Eggs is a member-owned, not-for-profit organisation providing marketing, research and development services to support Australian egg farmers.

Atelier Expressions announces the acquisition of French porcelain manufacturer Limoges JL Coquet

LIMOGES, France, Oct. 10, 2025 /PRNewswire/ — An iconic Limoges porcelain manufacturer since 1824, JL Coquet is opening a new chapter in its history by joining Atelier Expressions, a company recently created by TVS Venu International Holdings Pte Ltd. Based in Singapore, Atelier Expressions aims to promote exceptional companies and heritage skills.

Tara S. Venu, Executive Director, Atelier Expressions
Tara S. Venu, Executive Director, Atelier Expressions

This strategic alliance marks a major step forward for the manufacturer, renowned in particular for the excellence of its white porcelain. It is part of a commitment to international development and the promotion of craftsmanship, with a focus on passing on expertise and preserving jobs within the manufacturer.

‘I have always admired JL Coquet’s creations, which reflect a timeless heritage and impeccable craftsmanship,’ says Tara S. Venu, Executive Director of Atelier Expressions. “We are excited about the opportunities offered by this acquisition. The spirit of JL Coquet is perfectly in line with our ambition to bring international recognition to companies that embody exceptional quality and craftsmanship.”

Alongside Sébastien Cich, who continues his role as CEO of JL Coquet with the support of his team and the entire manufacturing staff, Renaud Paul-Dauphin joins Atelier Expressions in Paris. After heading up the tableware division of the Hermès group for several years, he brings recognised expertise in the sector.

A new dynamic is already taking shape: following the collaboration with designer Thomas Bastide for the Rêve collection, the opening of spaces in Seoul and New York, and the launch in 2026 of Studio Coquet, a creative laboratory dedicated to the big names in haute cuisine.

With more than 100 employees, including 85 artisans in Saint-Léonard-de-Noblat, JL Coquet remains faithful to its mission: to perpetuate the excellence of a rare craft shaped by hand and fire. Awarded the Entreprise du Patrimoine Vivant (Living Heritage Company) and IGP Limoges labels, the company embodies discreet and sustainable luxury. 

By joining Atelier Expressions, JL Coquet confirms its desire to promote the French art of living on the international stage. 

Press kit: https://14septembre.canto.global/b/PDCOV

Photo – https://laotiantimes.com/wp-content/uploads/2025/10/tara_s_venu.jpg
Photo – https://laotiantimes.com/wp-content/uploads/2025/10/atelier_1.jpg
Logo – https://laotiantimes.com/wp-content/uploads/2025/10/tvs_venu_international_logo.jpg

Limoges porcelain factory JL Coquet
Limoges porcelain factory JL Coquet

 

Taiwan Innotech Expo 2025: Showcasing Critical Role of AI in Transforming Industries, Explore Over 1,000 Cutting-Edge Innovations Across Three Exciting Themes

TAIPEI, Oct. 10, 2025 /PRNewswire/ — The annual Taiwan Innotech Expo (TIE), co-hosted by 11 major government agencies, including the Ministry of Economic Affairs, National Science and Technology Council, Ministry of Agriculture, Ministry of National Defense, Ministry of Education, Ministry of Labor, Ministry of Health and Welfare, Ministry of Environment, Ministry of Digital Affairs, National Development Council, and Academia Sinica, will take place from October 16, 2025, at Hall 1 of Taipei World Trade Center. This year’s theme, ” AI Cross-Domain Innovation, Driving the Smart Future,” will highlight the latest research and technological advancements across Taiwan’s five strategic industries. The Expo will feature three main pavilions: the Innovation Economy, Future Tech, and Sustainability. Attendees can expect to see significant advancements in sports-related technologies and AI applications in various fields and sectors.

Driving Upgrading of Industries and Fostering Global Partnerships via Cross-Sector AI Applications and Engaging Interactive Experiences

To facilitate AI integration across industries, the Expo will prominently feature related applications, comprising nearly half of the exhibits to underscore the momentum for industry upgrades. The event is designed to enhance attendees’ interactive and immersive experiences. For example, an AI activated by smartphones will assist attendees in navigating the exhibits. This three-day event aims to serve as a dynamic platform to align technologies with industry needs, foster international cooperation, and promote startup development.

On October 17, the “2025 Global Technology Matchmaking Event” will gather representatives from various global industries to explore potential collaborations with Taiwan-based teams, thus acting as a gateway to cross-border cooperation and technology commercialization. Additionally, the “IP Consultation Service” will offer a space for venture capitalists and service providers both in Taiwan and abroad to meet and discuss exciting business opportunities. Lastly, guided tours will facilitate investor engagement, linking investment opportunities with market prospects.

Official Website: https://tie.twtm.com.tw/en